ArticleGlobal health, epidemiology and genomics2019
Non-alcoholic fatty liver disease in Africa: a hidden danger.
Article in Global health, epidemiology and genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Hepatic Steatosis in People With Chronic Hepatitis B in Africa: Prevalence, Correlates, and Clinical Significance.Journal of viral hepatitis · 2026Article
- Impact of mucilage incorporation into xanthan gum on the physical and textural characteristics of gluten-free bread during short-term storage.Scientific reports · 2026Article
- Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Mean Platelet Volume as Predictors of Liver Fibrosis Severity in MASLD: A Cross-Sectional Study.Health science reports · 2026Article
- Editorial: Molecular insights into fatty liver disease: pathogenesis, progression, and therapeutic strategies.Frontiers in pharmacology · 2026Article
- Metabolic-associated steatotic liver disease in children and adolescents: a scoping review and narrative synthesis of epidemiology, risk factors, and screening approaches with emerging implications for sub-Saharan Africa.Frontiers in endocrinology · 2026Article
- Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis.Reviews in endocrine & metabolic disorders · 2025Review
- Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia.Journal of diabetes research · 2025Article
- Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross-Sectional Study.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- NON-ALCOHOLIC FATTY LIVER DISEASE AND RELATIONSHIP WITH ADIPOSITY IN NIGERIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE IBADAN EXPERIENCE.Annals of Ibadan postgraduate medicine · 2024Article
- Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients.Endocrinology, diabetes & metabolism · 2023Article
- Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Persons with Type 2 Diabetes Mellitus in Ghana: A Study of Prevalence, Severity, and Contributing Factors Using Transient Elastography.Journal of clinical medicine · 2023Article
- Hepatitis B in Africa Collaborative Network: cohort profile and analysis of baseline data.Epidemiology and infection · 2023Article
- Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia.BMJ open gastroenterology · 2022Article
- Hepatocellular Carcinoma in Africa: Challenges and Opportunities.Frontiers in medicine · 2022Article
- Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children.Frontiers in pediatrics · 2022Article
- Review
- Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome.World journal of virology · 2020Review
- A Review of Cancer Genetics and Genomics Studies in Africa.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a dearth of data on the burden and spectrum of non-alcoholic fatty liver disease (NAFLD) in African populations. The limited available information suggests that the prevalence of NAFLD in the general population is lowest for the Africa region. However, this is likely to be an underestimate and also does not take into consideration the long-term impact of rising rates of obesity, type-2 diabetes mellitus (T2DM) and high human immunodeficiency virus infection burden in Africa. A racial disparity in the prevalence of NAFLD has been observed in some studies but remains unexplained. There is an absence of data from population-based studies in Africa and this highlights the need for such studies, to reliably define the health service needs for this region. Screening for NAFLD at a population-based level using ultrasound is perhaps the ideal method for resource-poor settings because of its relative cost-effectiveness. What is required as a priority from Africa, are well-designed epidemiologic studies that screen for NAFLD in the general population as well as high-risk groups such as patients with T2DM or obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.